Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial
Pulse Biosciences, Inc. (NASDAQ:PLSE) is advancing bioelectric medicine through its proprietary Nano-Pulse Stimulation (NPS) technology, targeting immuno-oncology, dermatology, and cardiac ablation.